TABLE 2.
Distribution of clinical characteristics and their impact on prognosis (n = 446).
| OS | PFS | ||||||
|---|---|---|---|---|---|---|---|
| Variables | N (%) | MST (month) | HR (95% CI) | P Value | MST (month) | HR (95% CI) | P Value |
| Total no. of patients | 446 | — | — | — | — | — | — |
| Age | — | — | — | — | — | — | — |
| ≤56 | 225 (50.4) | 33.6 | 1.00 | — | 12.9 | 1.00 | — |
| >56 | 221 (49.6) | 31.7 | 1.05 (0.86,1.28) | 0.609 | 11.2 | 1.08 (0.89–1.31) | 0.454 |
| Sex | — | — | — | — | — | — | — |
| Female | 98 (22.0) | 35.7 | 1.00 | — | 17.5 | 1.00 | — |
| Male | 348 (78.0) | 30.2 | 1.15 (0.85–1.55) | 0.380 | 10.8 | 1.03 (0.76–1.39) | 0.842 |
| Histology | — | — | — | — | — | — | — |
| Adenocarcinoma | 201 (45.1) | 34.0 | 1.00 | — | 13.4 | 1.00 | — |
| Squamous carcinoma | 159 (35.7) | 42.0 | 0.79 (0.62–0.99) | 0.044* | 12.7 | 0.75 (0.60–0.95) | 0.015* |
| Small cell carcinoma | 55 (12.3) | 15.3 | 1.98 (1.32–2.96) | 0.001** | 8.2 | 1.59 (1.08–2.34) | 0.020* |
| Others | 31 (7.0) | 19.4 | 1.41 (0.96–2.08) | 0.081 | 9.4 | 1.01 (0.68–1.48) | 0.977 |
| Smoking status | — | — | — | — | — | — | — |
| Never | 166 (37.2) | 34.9 | 1.00 | — | 16.0 | 1.00 | — |
| Ever | 280 (62.8) | 28.8 | 1.10 (0.84–1.43) | 0.499 | 10.3 | 1.15 (0.88–1.50) | 0.304 |
| Clinical stage | — | — | — | — | — | — | — |
| -II/LD | 34 (7.6) | 27.4 | 1.00 | — | 13.3 | 1.00 | — |
| III-IV/ED | 412 (92.4) | 33.2 | 1.82 (1.13–2.94) | 0.015* | 11.7 | 1.92 (1.21–3.06) | 0.006** |
OS, overall survival; PFS, progression-free survival; LD, limited-stage disease; ED, extensive-stage disease; MST, median survival time; HR, hazard ratio; CI, confidence interval; *p < 0.05; **p < 0.01.